Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients

Gynecologic Oncology

Volumn 114, Issue 2, 2009, Pages 265-272

  Wang, Li ^a,b   Madigan, Michele C ^b,c   Chen, Hongmin ^a,b   Liu, FengHua ^a,b   Patterson, Kate I ^b,d   Beretov, Julia ^b,e   O'Brien, Philippa M ^b,d   Li, Yong ^b,e  

^a Henan Tumor Hospital   (China)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e ST GEORGE HOSPITAL   (Australia)

Author keywords

Epithelial ovarian cancer; Matrix metalloproteinase; Targeted therapy; Urokinase plasminogen activator; Urokinase plasminogen activator receptor

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE 14; PARAFFIN; UROKINASE; UROKINASE RECEPTOR;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STROMA CELL; TISSUE SECTION; TUMOR CELL;

ADULT; AGED; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 14; MIDDLE AGED; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PARAFFIN EMBEDDING; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 67549104876     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.04.031     Document Type: Article

References (41)

1. Zhang M., Lee A.H., and Binns C.W. Reproductive and dietary risk factors for epithelial ovarian cancer in China. Gynecol. Oncol. 92 (2004) 320-326
2. Bhoola S., and Hoskins W.J. Diagnosis and management of epithelial ovarian cancer. Obstet. Gynecol. 107 (2006) 1399-1410
3. Naora H., and Montell D.J. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nature Rev. Cancer 5 (2005) 355-366
4. Duffy M.J. The urokinase plasminogen activator system: role in malignancy. Curr. Pharm. Design 10 (2004) 39-49
5. Schmitt M., Wilhelm O.G., Reuning U., Kruger A., Harbeck N., Lengyel E., et al. The urokinase plasminogen activation system as a novel target for tumour therapy. Fibrinol. & Proteol. 14 (2000) 114-132
6. Morgan H., and Hill P.A. Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity. Cancer Cell Int. 5 (2005) 1
7. Sidenius N., and Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev. 22 (2003) 205-222
8. Casslen B., Bossmar T., Lecander I., and Astedt B. Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer. Eur. J. Cancer 30 (1994) 1302-1309
9. van der Burg M.E., Henzen-Logmans S.C., Berns E.M., van Putten W.L., Klijn J.G., and Foekens J.A. Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors. Int. J. Cancer 69 (1996) 475-479
10. Kuhn W., Schmalfeldt B., Reuning U., Pache L., Berger U., Ulm K., Harbeck N., Spathe K., Dettmar P., Hofler H., Janicke F., Schmitt M., and Graeff H. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br. J. Cancer 79 (1999) 1746-1751
11. Konecny G., Untch M., Pihan A., Kimmig R., Gropp M., Stieber P., Hepp H., Slamon D., and Pegram M. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clin. Cancer Res. 7 (2001) 1743-1749
12. Borgfeldt C., Hansson S.R., Gustavsson B., Masback A., and Casslen B. Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1). Int. J. Cancer 92 (2001) 497-502
13. Borgfeldt C., Bendahl P.O., Gustavsson B., Langstrom E., Ferno M., Willen R., Grenman S., and Casslen B. High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer. Int. J. Cancer 107 (2003) 658-665
14. Begum F.D., Hogdall E.V.S., Riisbro R., Christensen I.J., Engelholm S.A., Jorgensen M., Pedersen B.N., and Hogdall C.K. Prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) in Danish patients with recurrent epithelial ovarian cancer (REOC). APMIS 114 (2006) 675-681
15. Creasman W.J. Announcement, FIGO stages 1988. Revisions. Gynecol. Oncol. 5 (1989) 125-127
16. Seo S.S., Song Y.S., Kang D.H., Park I.A., Bang Y.J., Kang S.B., and Lee H.P. Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. Gynecol. Oncol. 92 (2004) 927-935
17. Cozzi P.J., Wang J., Delprado W., Madigan M.C., Russell P.J., and Li Y. Expression of urokinase plasminogen activator (uPA) and its receptor (uPAR) in the progression of prostate cancer: potential therapeutic targets. Human. Pathol. 37 (2006) 1442-1451
18. Buo L., Meling G.I., Karlsrud T.S., Johansen H.T., and Aasen A.O. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. Hum. Pathol. 26 (1995) 1133-1138
19. Foekens J.A., Peters H.A., Look M.P., Portengen H., Schmitt M., Kramer M.D., Brunner N., Janicke F., Meijer-van Gelder M.E., Henzen-Logmans S.C., van Putten W.L., and Klijn J.G. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 60 (2000) 636-643
20. Borgfeldt C., Casslen B., Liu C.L., Hansson S., Lecander I., and Astedt B. High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of uPA mRNA in poorly differentiated serous ovarian carcinoma. Int. J. Cancer 79 (1998) 588-595
21. Andreasen P.A., Kjoller L., Christensen L., and Duffy M.J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 72 (1997) 1-22
22. Schmitt M., Harbeck N., Thomssen C., Wilhelm O., Magdolen V., Reuning U., Ulm K., Hofler H., Janicke F., and Graeff H. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb. Haemost. 78 (1997) 285-296
23. Wei Y., Yang X., Liu Q., Wilkins J.A., and Chapman H.A. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J. Cell Biol. 144 (1999) 1285-1294
24. Andreasen P.A., Egelund R., and Petersen H.H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol. Life Sc. 57 (2000) 25-40
25. Binder B.R., Mihaly J., and Prager G.W. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb. Haemost. 97 (2007) 336-342
26. Pupa S.M., Menard S., Forti S., and Tagliabue E. New insights into the role of extracellular matrix during tumor onset and progression. J. Cell Physiol. 192 (2002) 259-267
27. Zhao Y., Lyons Jr. C.E., Xiao A., Templeton D.J., Sang Q.A., Brew K., and Hussaini I.M. Urokinase directly activates matrix metalloproteinases-9: a potential role in glioblastoma invasion. Biochem. Biophys. Res. Commun. 369 (2008) 1215-1220
28. He Y., Liu X.D., Chen Z.Y., Zhu J., Xiong Y., Li K., Dong J.H., and Li X. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis. Clin. Cancer Res. 13 (2007) 3115-3124
29. Graves L.E., Ariztia E.V., Navari J.R., Matzel H.J., Stack M.S., and Fishman D.A. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer Res. 64 (2004) 7045-7049
30. Schmalfeldt B., Prechtel D., Harting K., Spathe K., Rutke S., Konik E., Fridman R., Berger U., Schmitt M., Kuhn W., and Lengyel E. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin. Cancer Res. 7 (2001) 2396-2404
31. Egeblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. 2 (2002) 161-174
32. Kamat A.A., Fletcher M., Gruman L.M., Mueller P., Lopez A., Landen Jr. C.N., Han L., Gershenson D.M., and Sood A.K. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin. Cancer Res. 12 (2006) 1707-1714
33. Perigny M., Bairati I., Harvey I., Beauchemin M., Harel F., Plante M., and Tetu B. Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer. Am. J. Clin. Pathol. 129 (2008) 226-231
34. Trong P.L., Mao T.L., Chan W.Y., Huang S.C., and Lin C.T. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression. Gynecol. Oncol. 92 (2004) 559-567
35. Cai K.Q., Yang W.L., Capo-Chichi C.D., Vanderveer L., Wu H., Godwin A.K., and Xu X.X. Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis. Mol. Carcinogenesis 46 (2007) 130-143
36. Bramhall S.R., Rosemurgy A., Brown P.D., Bowry C., Buckels J.A., and Marimastat Pancreatic Cancer Study Group. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. Oncol. 19 (2001) 3447-3455
37. Pavlaki M., and Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev. 22 (2003) 177-203
38. Hess K.R., and Abbruzzese J.L. Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design. J. Clin. Oncol. 19 (2001) 3445-3446
39. Hofmeister V., Schrama D., and Becker J.C. Anti-cancer therapies targeting the tumor stroma. Cancer Immunol. Immunother. 57 (2008) 1-17
40. Song Y.J., Qu C.F., Rizvi S.M., Li Y., Robertson G., Raja C., Morgenstern A., Apostolidis C., Perkins A.C., and Allen B.J. Cytotoxicity of PAI2, C595 and herceptin vectors labeled with the alpha-emitting radioisotope bismuth-213 for ovarian cancer cell monolayers and clusters. Cancer Lett. 234 (2006) 176-183
41. Berkenblit A., Matulonis U.A., Kroener J.F., Dezube B.J., Lam G.N., Cuasay L.C., Brunner N., Jones T.R., Silverman M.H., and Gold M.A. A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. Gynecol. Oncol. 99 (2005) 50-57